Cart
sales@molnova.com
ABT-737
CAS No. 852808-04-9
ABT-737 ( ABT737;ABT 737 )
Catalog No. M16195 CAS No. 852808-04-9
A BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 58 | In Stock |
|
| 10MG | 69 | In Stock |
|
| 25MG | 125 | In Stock |
|
| 50MG | 222 | In Stock |
|
| 100MG | 390 | In Stock |
|
| 200MG | 574 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameABT-737
-
NoteResearch use only, not for human use.
-
Brief DescriptionA BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively.
-
DescriptionA BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; shows no inhibition against Mcl-1, Bcl-B or Bfl-1; induces the disruption of the BCL-2/BAX complex and BAK-dependent but BIM-independent activation of the intrinsic apoptotic pathway; exhibits single-agent-mechanism-based killing of cells from lymphoma and small-cell lung carcinoma lines, as well as primary patient-derived cells, and in animal models.Ovarian Cancer Phase 2 Clinical
-
SynonymsABT737;ABT 737
-
PathwayAngiogenesis
-
TargetBcl-2
-
RecptorBcl-2;Bcl-B;Bcl-w;Bcl-xL;Bfl-1
-
Research AreaCancer
-
IndicationOvarian Cancer
Chemical Information
-
CAS Number852808-04-9
-
Formula Weight813.43
-
Molecular FormulaC42H45ClN6O5S2
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESO=C(NS(=O)(C1=CC=C(N[C@H](CCN(C)C)CSC2=CC=CC=C2)C([N+]([O-])=O)=C1)=O)C3=CC=C(N4CCN(CC5=CC=CC=C5C6=CC=C(Cl)C=C6)CC4)C=C3
-
Chemical NameBenzamide, 4-[4-[(4'-chloro[1,1'-biphenyl]-2-yl)methyl]-1-piperazinyl]-N-[[4-[[(1R)-3-(dimethylamino)-1-[(phenylthio)methyl]propyl]amino]-3-nitrophenyl]sulfonyl]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Oltersdorf T, et al. Nature. 2005 Jun 2;435(7042):677-81.
2. Konopleva M, et al. Cancer Cell. 2006 Nov;10(5):375-88.
3. Tahir SK, et al. Cancer Res. 2007 Feb 1;67(3):1176-83.
2. Konopleva M, et al. Cancer Cell. 2006 Nov;10(5):375-88.
3. Tahir SK, et al. Cancer Res. 2007 Feb 1;67(3):1176-83.
molnova catalog
related products
-
A-1331852
A-1331852 is a potent and selective BCL-XL inhibitor (Ki<10 pM); shows much weaker affinity for BCL-2 (Ki=6 nM), BCL-W (Ki=4 nM), and MCL-1 (Ki=142 nM).
-
BCL6-IN-8
BCL6-IN-8 (BCL6-i) is a potent, irreversible and cell-active BCL6 inhibitor with inact/KI value of 1.9 × 104 M-1 s-1, targets Cys53 located at the protein-protein interaction interface.
-
Bcl-xL antagonist 2
Bcl-xL antagonist 2 is an effective and selective antagonist of Bcl-xL with an IC50 of 91 nM and a Ki of 65 nM. Bcl-xL antagonist 2 induces apoptosis in cancer cells and can be used in studies about chronic lymphocytic leukemia and non-Hodgkin’s lymphoma.
